Hyaluronic acid treatment of facial fat atrophy in HIV-positive patients

HIV Medicine

Volumn 8, Issue 8, 2007, Pages 475-482

  Bugge, H ^a   Negaard, A ^a   Skeie, L ^b   Bergersen, B ^c  

^a Department of Plastic Surgery ^*  (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antiretroviral therapy; Facial fat atrophy; HIV; Hyaluronicacid; SubQ

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; HYALURONIC ACID; STAVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ECHOGRAPHY; FACE DISORDER; FACE PROFILE; FEMALE; FEVER; HEALTH CARE COST; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE REACTION; LIPOATROPHY; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; RECURRENT INFECTION; ROSENBERG SELF-ESTEEM SCALE; SELF ESTEEM; SKINFOLD THICKNESS; SWELLING; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ADJUVANTS, IMMUNOLOGIC; ANTI-RETROVIRAL AGENTS; FACIAL HEMIATROPHY; FEMALE; HIV INFECTIONS; HUMANS; HYALURONIC ACID; MALE; MIDDLE AGED; PATIENT SATISFACTION; SELF CONCEPT; TREATMENT OUTCOME;

EID: 35448933249     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00494.x     Document Type: Article

References (24)

1. Duran S, Saves M, Spire B et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS 2001; 15: 2441-2444.
2. Echavez M, Horstman W. Relationship between lipoatrophy and quality of life. AIDS Read 2005; 15: 369-375.
3. Bergersen BM, Sandvik L, Ellingsen I, Bruun JN. Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive. HIV Med 2005; 6: 260-267.
4. Slama L, Lanoy E, Valantin MA, Bastard JP, Chermak A. Effect of pioglitazone on HIV-1 related lipoatrophy: A randomized double-blind placebo-controlled trial (ANRS 113) with 130 patients. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 151LB].
5. Kesselring UK. Efficacy and safety of polyacrylamide hydrogel for facial soft-tissue augmentation. Plast Reconstr Surg 2006; 118: 562-563.
6. Eppley BL, Dadvand B. Injectable soft-tissue fillers: Clinical overview. Plast Reconstr Surg 2006; 118: 98e-106e.
7. Friedman PM, Mafong EA, Kauvar AN, Geronemus RG. Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation. Dermatol Surg 2002; 28: 491-494.
8. Andre P. Evaluation of the safety of a non-animal stabilized hyaluronic acid (NASHA -Q-Medical, Sweden) in European countries: A retrospective study from 1997 to 2001. J Eur Acad Dermatol Venereol 2004; 18: 422-425.
9. Delorenzi C, Weinberg M, Solish N, Swift A. Multicenter study of the efficacy and safety of subcutaneous nonanimal-stabilized hyaluronic acid in aesthetic facial contouring: Interim report. Dermatol Surg 2006; 32: 208-215.
10. Bergersen BM, Sandvik L, Bruun JN. Body composition changes in 308 Norwegian HIV-positive patients. Scand J Infect Dis 2004; 36: 186-191.
11. Narins RS, Brandt F, Leyden J, Lorenc ZP, Rubin M, Smith S. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 2003; 29: 588-595.
12. Rosenberg M. Society and the Adolescent Self-Image, Revised edition. Middleton, CT: Wesleyan University Press, 1989.
13. Gooderham M, Solish N. Use of hyaluronic acid for soft tissue augmentation of HIV-associated facial lipodystrophy. Dermatol Surg 2005; 31: 104-108.
14. Valantin MA, Aubron-Olivier C, Ghosn J et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003; 17: 2471-2477.
15. Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 2005; 52: 233-239.
16. Lupton JR, Alster TS. Cutaneous hypersensitivity reaction to injectable hyaluronic acid gel. Dermatol Surg 2000; 26: 135-137.
17. Rongioletti F, Cattarini G, Sottofattori E, Rebora A. Granulomatous reaction after intradermal injections of hyaluronic acid gel. Arch Dermatol 2003; 139: 815-816.
18. Shafir R, Amir A, Gur E. Long-term complications of facial injections with Restylane (injectable hyaluronic acid). Plast Reconstr Surg 2000; 106: 1215-1216.
19. Serra-Renom JM, Fontdevila J. Treatment of facial fat atrophy related to treatment with protease inhibitors by autologous fat injection in patients with human immunodeficiency virus infection. Plast Reconstr Surg 2004; 114: 551-555.
20. Guaraldi G, Orlando G, De Fazio D et al. Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: A prospective study. Antiviral Ther 2005; 10: 753-759.
21. Homicz MR, Watson D. Review of injectable materials for soft tissue augmentation. Facial Plast Surg 2004; 20: 21-29.
22. Ghislanzoni M, Bianchi F, Barbareschi M, Alessi E. Cutaneous granulomatous reaction to injectable hyaluronic acid gel. Br J Dermatol 2006; 154: 755-758.
23. Cheng NX, Xu SL, Deng H et al. Migration of implants: A problem with injectable polyacrylamide gel in aesthetic plastic surgery. Aesthetic Plast Surg 2006; 30: 215-225.
24. Moyle GJ, Sabin CA, Cartledge J et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 2043-2050.